Bioventus Shares 2017 Science Summit Schedule, Enhancements to Bioventus Academy
DURHAM, NC – January 30, 2017 – Bioventus, a global leader in orthobiologics, today announced the dates of its 2017 Advances in Bone Healing Science Summits. Taking place on April 28 at the Grand Hyatt Denver in Denver, CO, on April 28 at the Novotel Schiphol Airport in Amsterdam, and on May 19 at the Westin Fort Lauderdale in Ft. Lauderdale, FL, these programs are geared toward geared towards practitioners who regularly treat fractures and patients with knee osteoarthritis (OA). Each one-day course is developed to allow participants a better understanding of treatment methods and the underlying biologic science through didactic presentations and in-depth case study discussions.
In 2017, Bioventus is also underwriting medical education programs at the American College of Foot and Ankle Surgeons 75th Anniversary Scientific Conference taking place February 27- March 2 in Las Vegas and the Physician Assistants in Orthopaedic Surgery 18th Annual Conference occurring August 21-25 in Baltimore.
In addition, Bioventus has launched several new web-based training courses on www.BioventusAcademy.com. Bioventus Academy is the company’s online medical education platform that provides clinicians with access to in-depth clinical and scientific information on bone healing, bone grafts and OA. The courses are titled: Bone Graft Substitutes, Bone Marrow Aspirate, EXOGEN® & Bone Healing, and DUROLANE® and Early OA Treatment Options.
“Bioventus is committed to becoming the global leader in orthobiologics but leadership is not only measured in sales or global footprint,” said Tony Bihl, CEO, Bioventus. “Furthering medical education for clinicians through both face-to-face and virtual channels underscores the commitment we have to partner with the healthcare community to help people resume and enjoy active lives.”
About Bioventus
Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. Bioventus has two product portfolios for orthobiologics, Bioventus Active Healing Therapies and Bioventus Surgical that make it a global leader in active orthopaedic healing. Its EXOGEN Ultrasound Bone Healing System is the #1 prescribed bone healing system in the US and is the only FDA-approved bone healing device that uses safe, effective ultrasound to stimulate the body’s natural healing process. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.BioventusGlobal.com and follow the company on Twitter @Bioventusglobal.
Media Contact:
Thomas Hill, +1 , [email protected]
Bioventus, the Bioventus logo, DUROLANE and EXOGEN are registered trademarks of Bioventus LLC.
Bioventus Names John Nosenzo Chief Commercial Officer
DURHAM, NC – January 23, 2017 – Bioventus, a global leader in orthobiologic solutions, today announced that it has named John Nosenzo as Chief Commercial Officer. Nosenzo brings more than 25 years of progressive sales and marketing leadership in pharmaceuticals and medical diagnostic markets to the company. He will be responsible for leading all global sales and distributor management functions for Bioventus, as well as global marketing for the Active Healing Therapies business, and the key customer interface functions responsible for expanding market access for our products and for providing reimbursement services for the EXOGEN® Ultrasound Bone Healing System.
Nosenzo will report to CEO Tony Bihl and be a member of the Bioventus executive leadership team. He will begin work on February 6.
“John is a natural charismatic leader who develops top talent, builds strong teams, and consistently delivers exceptional sales results,” said Tony Bihl. “We are very pleased he is joining us to lead our commercial organization and look forward to the impact he will make with our customers and our commercial team and processes, to fully capture the global market potential for Bioventus’ expanding product portfolio.”
Prior to joining Bioventus, Nosenzo was Senior Vice President, Global Customer Operations at Beckman Coulter Diagnostics since 2011. Previously, he was Senior Vice President, Customer Relations Management for Siemens Healthcare, and Vice President, Marketing and Sales at Quest Diagnostics.
Nosenzo began his career with Bayer Healthcare, progressively growing thorough sales leadership roles in pharmaceuticals and diagnostic testing businesses over 20+ years, ultimately achieving the role of Senior Vice President, General Manager- Americas for Bayer Diagnostics, prior to the acquisition of this business by Siemens AG.
He earned an MBA in marketing and management from Adelphi University and a Bachelor of Science in pharmacy from St. John’s University.
About Bioventus
Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. Bioventus has two product portfolios for orthobiologics, Bioventus Active Healing Therapies and Bioventus Surgical that make it a global leader in active orthopaedic healing. Its EXOGEN Ultrasound Bone Healing System is the #1 prescribed bone healing system in the US and is the only FDA-approved bone healing device that uses safe, effective ultrasound to stimulate the body’s natural healing process. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide.For more information, visit www.BioventusGlobal.com and follow the company on Twitter @Bioventusglobal
Media Contact:
Thomas Hill, +1 , [email protected]
Bioventus, the Bioventus logo and EXOGEN are registered trademarks of Bioventus LLC.
Bioventus Selects MEDSERVICE to Distribute DUROLANE in Russia
HOOFDDORP, THE NETHERLANDS – January 17, 2017– Bioventus, a leader in orthobiologic solutions, announced it has selected MEDSERVICE to distribute DUROLANE® in Russia. DUROLANE is a single-injection joint-fluid based on a natural, safe and proven technology process called NASHA® which yields stabilized hyaluronic acid (HA). Hyaluronic acid is a naturally occurring molecule that provides the lubrication and cushioning in a normal joint.
In Russia, MEDSERVICE will offer DUROLANE (3ml) that is indicated for the symptomatic treatment of mild to moderate knee or hip osteoarthritis (OA) and DUROLANE SJ (1ml) associated with mild to moderate osteoarthritis pain in the ankle, elbow, wrist, fingers, and toes. MEDSERVICE, which provides a range of services to medical institutions of regional and federal levels, will distribute DUROLANE to clinicians in the Moscow metropolitan area and throughout all regions of Russia.
“We are pleased to make DUROLANE available to patients in Russia again,” said Tony Bihl, CEO, Bioventus. “This market is important to our growth in Europe and our international growth strategy overall as we strive to bring our orthobiologic solutions to patients worldwide.”
“MEDSERVICE is off to a great start with DUROLANE in Moscow and we will quickly expand to other cities and regions in Russia this year,” said Andrew McCartney, Managing Director International, for Europe, Middle East and Africa, Bioventus. “The MEDSERVICE team, and the company’s objective to help increase and develop the range of medical products and services provided to patients, is in complete alignment with Bioventus as we work together with the health care community in Russia to help people resume and enjoy active lives.”
“We are very excited to work with Bioventus to market DUROLANE in Russia,” said Alexander Yagodin, Managing Director, MEDSERVICE. “This innovative single-injection solution will safely help millions of patients better manage the pain associated with knee osteoarthritis.”
About Bioventus
Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. Bioventus has two product portfolios for orthobiologics, Bioventus Active Healing Therapies and Bioventus Surgical that make it a global leader in active orthopaedic healing. Its EXOGEN®Ultrasound Bone Healing System is the #1 prescribed bone healing system in the US and is the only FDA-approved bone healing device that uses safe, effective ultrasound to stimulate the body’s natural healing process. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide.
For more information, visit www.BioventusGlobal.com and follow the company on Twitter @Bioventusglobal.
Bioventus, the Bioventus logo, EXOGEN and DUROLANE are registered trademarks and GELSYN-3, is a trademark of Bioventus LLC. SUPARTZ FX is a trademark of Seikagaku Corporation.
Media Contact:
Thomas Hill, +1 , [email protected]
DUROLANE - Indications
DUROLANE (3ml) is indicated for the symptomatic treatment of mild to moderate knee or hip osteoarthritis (OA) and DUROLANE SJ (1ml) associated with mild to moderate osteoarthritis pain in the ankle, elbow, wrist, fingers, and toes.
There are no known contraindications. You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children. Risks can include transient pain, swelling and/or stiffness at the injection site. Clinical effectiveness has been demonstrated out to six months but results may vary depending on various patient factors.
Bioventus, the Bioventus logo, EXOGEN and DUROLANE are registered trademarks of Bioventus LLC. NASHA is a registered trademark of Galderma S.A.
